Skip to content
DataLookout
Menu

NCT04910022

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

StatusTerminated
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Per the protocol, the sponsor reserves the right to discontinue the trial for valid scientific or administrative reasons. The discontinuation of the study is not related to safety issues. Show 5 more changesShow less
    • Eligibility criteria expanded, about 40 words
    • Trial sites reduced: 18 → 12 locations
    • Final enrollment: 80 participants (planned 150)
    • Primary completion date changed from estimate of May 30, 2027 to May 6, 2026
    • Secondary endpoints: details revised at 6 of 20 entries
  2. Notable Primary completion date: Jun 30, 2025 to May 30, 2027
    • Study completion date: Nov 30, 2025 to Sep 7, 2027
    v11
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 18 of 18 sites
    v10
  4. Minor Study sites: 11 to 18v9
  5. Minor Study sites: 10 to 11v8
Show 6 earlier versionsHide 6 earlier versions
  1. Minor Study sites: 5 to 10v7
  2. Notable Enrollment target: 75 to 150
    • Eligibility criteria expanded, about 309 words
    • Secondary endpoints: details revised at 11 of 20 entries
    v6
  3. Notable Enrollment target: 125 to 75v5 Show 5 more changesShow less
    • Eligibility criteria expanded, about 74 words
    • Primary endpoints revised (2)
    • Interventions: Lomustine (Drug), NMS-03305293 + TMZ (Drug), NMS-03305293 + TMZ (Drug), NMS-03305293 + TMZ (Drug) to NMS-03305293 (Drug), Temozolomide (Drug)
    • Secondary endpoints: 18 to 20
    • Study arms: 4 to 1
  4. Minor Study sites: 4 to 5v4
  5. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Dec 31, 2024 to Jun 30, 2025
    • Study completion date: May 30, 2025 to Nov 30, 2025
    • Start date changed from estimate of Sep 30, 2021 to Dec 1, 2021
    • Site details revised at 4 of 4 sites
  6. Notable Start date: May 28, 2021 to Sep 30, 2021v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase 1: Number of Participants with first-cycle dose limiting toxicity
Timeframe: Time interval between the first dose administration in Cycle 1 and the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to drug related toxicity
Phase 2: Objective Response Rate
Timeframe: From the date of first response up to data cut-off (approximately 18 months)

Secondary (20)

Number of participants with Adverse Events (AEs)
Maximum concentration (Cmax) of NMS-03305293 and possible identified metabolites (if appropriate) after single and multiple doses of drug
Time to observed Cmax (Tmax) of NMS-03305293 and possible identified metabolites (if appropriate) after single and multiple doses of drug
Area under the concentration-time curve up to the last detectable plasma concentration (AUClast) of NMS-03305293 and possible identified metabolites (if appropriate) after single and repeated dose of drug.
Terminal elimination half-life (t1/2) of NMS-03305293 and possible identified metabolites (if appropriate) after single and multiple doses of drug
Show 15 moreShow less
Area under the plasma concentration vs. time curve to infinity (AUCinf) of NMS-03305293 and possible identified metabolites (if appropriate) after multiple doses of drug.
Accumulation ratio (Rac) of NMS-03305293 and possible identified metabolites (if appropriate) after multiple doses of drug.
Oral plasma clearance (CL/F) of NMS-03305293 and possible identified metabolites (if appropriate) after multiple doses of drug
Apparent volume of distribution (Vd/F) of NMS-03305293 and possible identified metabolites (if appropriate) after multiple doses of drug
Phase 1: Renal clearance of NMS-03305293 and possible identified metabolites (if appropriate) after multiple doses of drug
Phase 1: Cumulative amount recovered unchanged in the urine (Ae) of NMS-03305293 and possible identified metabolites (if appropriate) after multiple doses of drug
Phase 1: Cumulative amount recovered unchanged in the urine expressed as a fraction of administered dose (Ae%) of NMS-03305293 and possible identified metabolites (if appropriate) after multiple doses of drug
Phase 1: Objective Tumor Response
Phase 1: Duration of Response
Phase 1: Progression Free Survival
Phase 2: Duration of response (DoR) through central retrospective assessment of RANO criteria
Phase 2: Progression-free survival (PFS)
Phase 2: 6-month PFS Rate
Phase 2: 9 and 12-Months Overall Survival Rates
Overall Survival

Arms and interventions

NMS-03305293 +TMZExperimental

Phase 1 Dose Escalation: All patients will receive NMS-03305293 and temozolomide (TMZ) administered orally (NMS-03305293 once or twice daily on days 1-7 or 28 consecutive days from Day 1 to Day 28; TMZ once daily on days 1-5;) in repeated 4-week cycles aimed at defining the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Doses (RP2Ds) of NMS-03305293 in combination with TMZ. Each cycle is 28 days. Phase 2: Once the RP2D is defined, the patients will receive TMZ daily on days 1-5 in combination with NMS-03305293 at the RP2D on days 1-7 or on days 1-28 every 28 days. Backfill cohorts: additional patients may be treated with TMZ daily on days 1-5 and NMS-03305293 at different dose levels/schedules that have been previously assessed and determined to be safe, in order to properly characterize the exposure relationship over a range of doses/schedules. The backfill cohorts may run in parallel.

Drugs: NMS-03305293, Temozolomide

Sites

12 sites in 4 countries

United States 7, Italy 3, Netherlands 1, Switzerland 1